Skip to main content
SpringerLink
Log in

Pretransplant Assessment for Hematopoietic Cell Transplantation Recipients and Donors

  • Chapter
  • First Online:
Blood and Marrow Transplant Handbook

  • 1141 Accesses

Abstract

Hematopoietic cell transplantation (HCT) offers the best chance for prolonged disease control in many hematologic malignancies. Developments in reduced intensity conditioning (RIC) and improvements in supportive care have allowed HCT to expand to older individuals, but transplant-related mortality (TRM) continues to remain a barrier to transplant utilization and success. As HCT expands to less fit individuals, refining pretransplant assessment is necessary to guide patient selection.

This chapter reviews disease indications for HCT, metrics used for pre-HCT patient assessment, general eligibility guidelines, and HCT donor evaluation. A broad understanding of patient health prior to HCT is critical in optimizing not only patient and conditioning regimen selection, but also in developing individualized patient counseling and supportive care plans.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 149.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 199.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Muffly L, Pasquini MC, Martens M, et al. Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States. Blood. 2017;130(9):1156–64.

    Article  CAS  Google Scholar 

  2. Majhail NS, Farnia SH, Carpenter PA, et al. Indications for autologous and allogeneic hematopoietic cell transplantation: guidelines from the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2015;21(11):1863–9.

    Article  Google Scholar 

  3. Bullinger L, Dohner K, Dohner H. Genomics of acute myeloid leukemia diagnosis and pathways. J Clin Oncol. 2017;35(9):934–46.

    Article  CAS  Google Scholar 

  4. Dohner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424–47.

    Article  Google Scholar 

  5. Kassim AA, Savani BN. Hematopoietic stem cell transplantation for acute myeloid leukemia: a review. Hematol Oncol Stem Cell Ther. 2017;10(4):245–51.

    Article  CAS  Google Scholar 

  6. Shen Z, Gu X, Mao W, et al. Influence of pre-transplant minimal residual disease on prognosis after Allo-SCT for patients with acute lymphoblastic leukemia: systematic review and meta-analysis. BMC Cancer. 2018;18(1):755.

    Article  Google Scholar 

  7. Aldoss I, Pullarkat V. Indications for allogeneic hematopoietic cell transplantation for adults with Philadelphia-chromosome negative acute lymphoblastic leukemia in first complete remission: all about MRD? Bone Marrow Transplant. 2019;54(1):3–5.

    Article  Google Scholar 

  8. Giebel S, Marks DI, Boissel N, et al. Hematopoietic stem cell transplantation for adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first remission: a position statement of the European Working Group for Adult Acute Lymphoblastic Leukemia (EWALL) and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant. 2019;54(6):798–809. https://doi.org/10.1038/s41409-018-0373-4.

  9. Litzow MR, Fielding AK, Luger SM, et al. The evolving role of chemotherapy and hematopoietic cell transplants in Ph-positive acute lymphoblastic leukemia in adults. Bone Marrow Transplant. 2017;52(12):1592–8.

    Article  CAS  Google Scholar 

  10. Della Porta MG, Tuechler H, Malcovati L, et al. Validation of WHO classification-based Prognostic Scoring System (WPSS) for myelodysplastic syndromes and comparison with the revised International Prognostic Scoring System (IPSS-R). A study of the International Working Group for Prognosis in myelodysplasia (IWG-PM). Leukemia. 2015;29(7):1502–13.

    Article  CAS  Google Scholar 

  11. Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120(12):2454–65.

    Article  CAS  Google Scholar 

  12. Zeidan AM, Lee JW, Prebet T, et al. Comparison of the prognostic utility of the revised international prognostic scoring system and the French prognostic scoring system in azacitidine-treated patients with myelodysplastic syndromes. Br J Haematol. 2014;166(3):352–9.

    Article  CAS  Google Scholar 

  13. de Witte T, Bowen D, Robin M, et al. Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel. Blood. 2017;129(13):1753–62.

    Article  Google Scholar 

  14. Salit RB, Deeg HJ. Transplant decisions in patients with myelofibrosis: should mutations be the judge? Biol Blood Marrow Transplant. 2018;24(4):649–58.

    Article  Google Scholar 

  15. Elsawy M, Sorror ML. Up-to-date tools for risk assessment before allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2016;51(10):1283–300.

    Article  CAS  Google Scholar 

  16. Kennedy VE, Muffly LS. Assessment of older adult candidates for allogeneic hematopoietic cell transplantation: updates and remaining questions. Expert Rev Hematol. 2019;11:1–8.

    Google Scholar 

  17. Sorror ML. How I assess comorbidities before hematopoietic cell transplantation. Blood. 2013;121(15):2854–63.

    Article  CAS  Google Scholar 

  18. Wais V, Bunjes D, Kuchenbauer F, Sorror ML. Comorbidities, age, and other patient-related predictors of allogeneic hematopoietic cell transplantation outcomes. Expert Rev Hematol. 2018;11(10):805–16.

    Article  CAS  Google Scholar 

  19. Armand P, Gibson CJ, Cutler C, et al. A disease risk index for patients undergoing allogeneic stem cell transplantation. Blood. 2012;120(4):905–13.

    Article  CAS  Google Scholar 

  20. Sorror ML, Storer BE, Fathi AT, et al. Development and validation of a novel acute myeloid leukemia-composite model to estimate risks of mortality. JAMA Oncol. 2017;3(12):1675–82.

    Article  Google Scholar 

  21. FACT-JACIE international standards for cellular therapy product collection, processing, and administration. 7th Ed. 2017.

    Google Scholar 

  22. Tiercy JM. How to select the best available related or unrelated donor of hematopoietic stem cells? Haematologica. 2016;101(6):680–7.

    Article  CAS  Google Scholar 

  23. Sun YQ, Chang YJ, Huang XJ. Update on current research into haploidentical hematopoietic stem cell transplantation. Expert Rev Hematol. 2018;11(4):273–84.

    Article  CAS  Google Scholar 

  24. Twillman RK, Manetto C, Wellisch DK, Wolcott DL. The Transplant Evaluation Rating Scale. A revision of the psychosocial levels system for evaluating organ transplant candidates. Psychosomatics. 1993;34(2):144–53.

    Article  CAS  Google Scholar 

  25. Foster LW, McLellan L, Rybicki L, et al. Utility of the psychosocial assessment of candidates for transplantation (PACT) scale in allogeneic BMT. Bone Marrow Transplant. 2009;44(6):375–80.

    Article  CAS  Google Scholar 

  26. Maldonado JR, Dubois HC, David EE, et al. The Stanford Integrated Psychosocial Assessment for Transplantation (SIPAT): a new tool for the psychosocial evaluation of pre-transplant candidates. Psychosomatics. 2012;53(2):123–32.

    Article  Google Scholar 

  27. Sorror ML, Maris MB, Storb R, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106(8):2912–9.

    Article  CAS  Google Scholar 

  28. Sorror ML, Storb RF, Sandmaier BM, et al. Comorbidity-age index: a clinical measure of biologic age before allogeneic hematopoietic cell transplantation. J Clin Oncol. 2014;32(29):3249–56.

    Article  Google Scholar 

  29. Muffly LS, Kocherginsky M, Stock W, et al. Geriatric assessment to predict survival in older allogeneic hematopoietic cell transplantation recipients. Haematologica. 2014;99(8):1373–9.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology and Oncology, University of California, San Francisco, San Francisco, CA, USA

    Vanessa E. Kennedy

  2. Department of Internal Medicine, Division of Blood and Marrow Transplantation, Stanford University School of Medicine, Stanford, CA, USA

    Lori S. Muffly

Authors
  1. Vanessa E. Kennedy
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lori S. Muffly
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lori S. Muffly .

Editor information

Editors and Affiliations

  1. Center for Hematologic Malignancies Adult Blood and Marrow Transplant & Cell Therapy Program, Knight Cancer Institute Oregon Health & Science University, Portland, OR, USA

    Richard T. Maziarz

  2. Center for Hematologic Malignancies Adult Blood and Marrow Transplant & Cell Therapy Program, Knight Cancer Institute Oregon Health & Science University, Portland, OR, USA

    Susan Schubach Slater

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Kennedy, V.E., Muffly, L.S. (2021). Pretransplant Assessment for Hematopoietic Cell Transplantation Recipients and Donors. In: Maziarz, R.T., Slater, S.S. (eds) Blood and Marrow Transplant Handbook. Springer, Cham. https://doi.org/10.1007/978-3-030-53626-8_4

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-53626-8_4

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-53625-1

  • Online ISBN: 978-3-030-53626-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation